Despite ILD being a leading cause of death in RA patients, there are no clinical guidelines for monitoring this lung condition in this population, experts say.
Guidelines could tailor cardiovascular risk scores by using a multiplier of 2.5 for systemic sclerosis, 2.0 for lupus, and 1.5 for any other rheumatic disease.
Gender-affirming hormone therapy does not need to be a strict contraindication in transgender patients with rheumatic disease, an author of a new case series and systematic review said.
The Food and Drug Administration has approved a new diagnostic blood test to detect monospecific Ribosomal P antibodies to support a diagnosis of systemic lupus erythematosus.